Moderna co-founder is a billionaire once again at $1.7 billion - he once turned down 20 high-paying job offers to ‘have more of an impact on the world’

{
  "signal_id": "a2ee0bb3-8310-8acc-3f61-7dfc523a13ab",
  "signal_type": "news",
  "signal_subtype": "partners_with",
  "detected_at": "2026-08-20T15:23:13+00:00",
  "company": {
    "name": "Moderna",
    "domain": "modernatx.com"
  },
  "data": {
    "url": "https://fortune.com/2026/08/20/moderna-cofounder-robert-langer-billionaire-again-1-7-billion-once-turned-down-20-high-paying-job-offers-have-more-impact-on-world/",
    "title": "Moderna co-founder is a billionaire once again at $1.7 billion - he once turned down 20 high-paying job offers to ‘have more of an impact on the world’",
    "author": "Emma Burleigh",
    "excerpt": "The net worths of CEOs and founders are largely at the whim of their company stock - all it takes is one breakout earnings report or blockbuster news to shake up their fortunes. Now, Moderna cofounder Robert Langer has re-entered the billionaires club following promising cancer vaccine trials that sent the company’s stock soaring. Langer, known as the “ Edison of Medicine,” witnessed his equity in the biotech business double in value, shooting his net worth up to roughly $1.7 billion, according to a Forbes analysis . His wealth surge followed the news this Wednesday that Moderna and pharmaceutical company Merck’s mRNA cancer vaccine hit its goals in a Phase 3 trial targeting melanoma. The announcement sent Modern’s stock soaring more than 100%, valuing Langer’s roughly 3% stake past the billion-dollar threshold - a massive jump from the roughly $730 million he boasted on Tuesday. This is the second time that Langer has made it to the billionaires club. Langer first came into 10-figure wealth back in November 2020, when Moderna shares surged after the company reported promising Phase 3 results for its COVID-19 vaccine. During the pandemic-era Moderna boom, Forbes even put his net worth as high as $4.9 billion in 2021, before plunging and knocking him out of the club. The 77-year-old cofounder’s stake was estimated to be just $343 million when Modern’s shares were at a...",
    "product": "mRNA cancer vaccine",
    "summary": "Moderna and Merck's mRNA cancer vaccine successfully met its goals in a Phase 3 trial for melanoma.",
    "planning": false,
    "image_url": "https://fortune.com/img-assets/wp-content/uploads/2026/08/GettyImages-472982424-e1787238301268.jpg?resize=1200,600",
    "confidence": 0.9,
    "product_data": {
      "name": "mRNA cancer vaccine",
      "full_text": "mRNA cancer vaccine",
      "fuzzy_match": false
    },
    "product_tags": [
      "medical"
    ],
    "published_at": "2026-08-20T15:23:13Z",
    "vulnerability": "melanoma",
    "effective_date": "2026-08-19",
    "article_sentence": "His wealth surge followed the news this Wednesday that Moderna and pharmaceutical company Merck’s mRNA cancer vaccine hit its goals in a Phase 3 trial targeting melanoma.",
    "related_company_name": "Merck",
    "related_company_domain": "merck.com"
  }
}

curl https://signals.autobound.ai/v1/signals/a2ee0bb3-8310-8acc-3f61-7dfc523a13ab \
  -H "X-API-KEY: $AUTOBOUND_API_KEY"

curl -X POST https://signals.autobound.ai/v1/companies/enrich \
  -H "X-API-KEY: $AUTOBOUND_API_KEY" \
  -H "Content-Type: application/json" \
  -d '{"domain":"modernatx.com","limit":20}'